

Certificate holder	Protocol Title	Site(s)
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19	Prince of Wales Hospital
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with moderate COVID-19 compared to standard of care treatment	Prince of Wales Hospital
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19	Princess Margaret Hospital
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with moderate COVID-19 compared to standard of care treatment	Princess Margaret Hospital
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19	Queen Mary Hospital
Gilead Sciences Hong Kong Limited	A phase 3 randomized study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with moderate COVID-19 compared to standard of care treatment	Queen Mary Hospital
Parexel International (Hong Kong) Company Limited	A randomized, double-blind, placebo-controlled, phase Ib/II clinical study to evaluate the preliminary efficacy, safety, pharmacokinetic profiles and immunogenicity of JS016 (recombinant human anti-SARS-CoV-2 monoclonal antibody) given as intravenous infusion in participants with mild and moderate COVID-19 or of SARS-CoV-2 asymptomatic infection	Queen Mary Hospital
Novotech Clinical Research (HK) Ltd.	A phase 2, randomized, single-blinded, placebo-controlled study to evaluate the safety and efficacy of human monoclonal antibodies, BR11-196 and BR11-198, administered sequentially by intravenous infusion for the treatment of COVID-19 patients	Queen Mary Hospital
Research Pharmaceutical Services, Clinical Trials Centre, The University of Hong Kong	A phase 1, randomized, double-blinded, placebo-controlled, dose-escalation and dose-expansion study to evaluate the safety and immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 in healthy adults	Phase 1 Clinical Trials Centre, The University of Hong Kong

Certificate holder	Protocol Title	Site(s)
Dr. LAU Yu-lung	To compare the reactogenicity and immunogenicity of the recommended COVID-19 vaccines in young adolescents and children in Hong Kong	1. Ap Lei Chau Vaccination Centre 2. Queen Mary Hospital 3. HKU Community Vaccination Centre at Gleneagles Hospital Hong Kong 4. Community Vaccination Center at Sun Yat Sen Memorial Park Sports Centre
Dr. TANG Siu-fai	Immunogenicity of third dose of SARS-CoV-2 vaccine in non-responders after standard 2-dose SARS-CoV-2 vaccination	Hong Kong Sanatorium & Hospital
Dr. HUI S.C. David	Long-term longitudinal comparisons of health and immunity status in convalescent COVID-19 and vaccinated cohorts in Hong Kong	1. Prince of Wales Hospital 2. The CUHK Medical Centre
Prof. COWLING J. Benjamin	Randomized trial of COVID-19 booster vaccinations (Cobovax Study)	Community Vaccination Centre (Gleneagles Hospital Hong Kong)
Prof. COWLING J. Benjamin	mRNA vaccination to boost antibodies against SARS-CoV-2 in recipients of inactivated vaccines (the mBoost study)	Community Vaccination Centre (Gleneagles Hospital Hong Kong)
Research Pharmaceutical Services, Clinical Trials Centre, The University of Hong Kong	A randomized, double-blinded, placebo-controlled study to evaluate the safety and immunogenicity of DeINS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 or 3 doses of BNT162b2	Phase 1 Clinical Trials Centre, The University of Hong Kong
Sinovac Biotech (Hong Kong) Limited	A phase IIb, randomized, double-blinded trial to evaluate the immunogenicity and safety study of the booster dose using the high or medium dose of COVID-19 vaccine (vero cell), inactivated in healthy adults who have completed two doses of mRNA vaccine in Hong Kong	Gleneagles Hospital Hong Kong
Research Pharmaceutical Services, Clinical Trials Centre, The University of Hong Kong	A randomized, double-blinded cohort clinical study evaluating the safety and immunogenicity of sequential immunization of two doses of BIBP inactivated COVID-19 vaccine (Omicron), WIBP inactivated COVID-19 vaccine (Omicron) or inactivated COVID-19 vaccine (prototype) in population aged 18 years and above who have completed two or three doses of inactivated or mRNA vaccine	Community Vaccination Centre (Sun Yat Sen Memorial Park Sports Centre)
Sinovac Biotech (Hong Kong) Limited	A phase IIb, randomized, open-labeled trial to evaluate the immunogenicity and safety of one or two doses of booster vaccine with the COVID-19 vaccine (Vero Cell), inactivated, Omicron strain in adults above 18 years old who have completed two or three doses of mRNA vaccine or CoronaVac® in Hong Kong	Gleneagles Hospital Hong Kong

Certificate holder	Protocol Title	Site(s)
IQVIA RDS HONG KONG LIMITED	A multicenter, double-blind, randomized, placebo-controlled, phase II/III study to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early treatment of coronavirus disease 2019 (COVID-19) in participants with mild to moderate COVID-19	Phase I Clinical Trial Centre, The Chinese University of Hong Kong
IQVIA RDS HONG KONG LIMITED	A multicenter, double-blind, randomized, placebo-controlled, phase II/III study to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early treatment of coronavirus disease 2019 (COVID-19) in participants with mild to moderate COVID-19	CUHK Medical Centre